Literature DB >> 18196598

Development of a pituitary-specific cre line targeted to the Pit-1 lineage.

Zhirong Yin1, Lisa Williams-Simons, Lisa Rawahneh, Sylvia Asa, Lawrence S Kirschner.   

Abstract

Tissue-specific expression of the Cre recombinase is a well-established genetic tool to analyze gene function in specific tissues and cell types. In this report, we describe the generation of a new transgenic line that expresses Cre under the control of the rat growth hormone releasing hormone receptor (rGhrhr) promoter. This promoter, chosen to target the anterior pituitary, drives cre-mediated recombination in cells of the Pit1 lineage, including somatotrophs, lactotrophs, and thyrotrophs. Cre activity is first detected at embryonic day 13.5, and gradually increases to reach high level expression by postnatal day 2. In addition to the pituitary, rGhrhr-cre expression was detected in vibrissae and in hair follicles of the proximal limb, but not in other tissues. The rGhrhr-cre line will be a valuable tool for the study of the development of the pituitary Pit1 lineage and for the study of tumorigenesis involving these cells. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196598     DOI: 10.1002/dvg.20362

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  10 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

Review 2.  Mouse models of endocrine tumours.

Authors:  Georgette N Jones; Parmeet K Manchanda; Daphne R Pringle; Mei Zhang; Lawrence S Kirschner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

3.  Adipocyte Versus Somatotrope Leptin: Regulation of Metabolic Functions in the Mouse.

Authors:  Angela Katherine Odle; Melody Allensworth-James; Anessa Haney; Noor Akhter; Mohsin Syed; Gwen V Childs
Journal:  Endocrinology       Date:  2016-02-09       Impact factor: 4.736

4.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

5.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

6.  Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling.

Authors:  Madson Q Almeida; Michael Muchow; Sosipatros Boikos; Andrew J Bauer; Kurt J Griffin; Kit Man Tsang; Chris Cheadle; Tonya Watkins; Feng Wen; Matthew F Starost; Ioannis Bossis; Maria Nesterova; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

Review 7.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

8.  Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis.

Authors:  Zhirong Yin; Lisa Williams-Simons; A F Parlow; Sylvia Asa; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2007-11-01

9.  Acromegaly due to a Macroinvasive Plurihormonal Pituitary Adenoma and a Rectal Carcinoid Tumor.

Authors:  Sang Ouk Chin; Jin Kyung Hwang; Sang Youl Rhee; Suk Chon; Seungjoon Oh; Misu Lee; Natalia S Pellegata; Sung Woon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2015-01-05

10.  Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.

Authors:  P K Manchanda; G N Jones; A A Lee; D R Pringle; M Zhang; L Yu; K M D La Perle; L S Kirschner
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.